Skip to content

Effect of lactoferrin for vaginitis and cervicitis in obstetrics

Evaluation of improvement of bacterial flora in pregnant women by lactoferrin tablets

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs021190020
Enrollment
40
Registered
2020-02-18
Start date
2020-02-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vacterial vaginitis, threatened preterm birth

Interventions

Give enteric lactoferrin to pregnant women with abnormal vaginal flora
Clinical Trials, Phase II as Topic

Sponsors

Miura Hiroshi
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1) Maternal age: 20 years old or older, under 50 years 2) Pregnant women who plan to deliver in our department 3) Patients who have been diagnosed with intractable vaginitis or cervicitis, and who have not improved their vaginal discharge findings with conventional treatment

Exclusion criteria

Exclusion criteria: If not gain consent

Design outcomes

Primary

MeasureTime frame
1. Intractable vagus or cervical inflammation patients improve vaginal discharge findings by taking lactoferrin-enter-soluble tablets 2. Preterm Birth Rate of Pregnant Women With Lactoferrin Enter-Dissolved Tablets

Secondary

MeasureTime frame
Evaluation of side effects and other safety caused by lactoferrin-enter-lytic tablets

Contacts

Public ContactHiroshi Miura

Akita University Hospital

miurah@doc.med.akita-u.ac.jp+81-18-884-6163

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026